» Articles » PMID: 30815820

Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care

Overview
Journal Dig Dis Sci
Specialty Gastroenterology
Date 2019 Mar 1
PMID 30815820
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Current guidelines recommend starting colorectal cancer (CRC) surveillance 8-10 years after inflammatory bowel disease (IBD) onset. Recent studies report that the incidence of CRC within 8-10 years of IBD onset (i.e., early CRC) ranges from 12 to 42%.

Aims: To describe the current prevalence of early CRC in a tertiary care center IBD cohort with CRC and to identify associated risk factors.

Methods: We performed a single-center observational study of IBD patients diagnosed with CRC from 2005 to 2015. We compared characteristics of patients with early CRC (diagnosis of CRC within 8 years of initial IBD onset) to those with CRC diagnosed later in their IBD course.

Results: Ninety-three patients met inclusion criteria. Eleven (11.8%) patients developed CRC within 8 years of initial IBD onset. On multivariable logistic regression, age greater than 28 at IBD onset (adjusted OR 12.0; 95% CI 2.30, 62.75) and tobacco use (adjusted OR 8.52; 95% CI 1.38, 52.82) were significant predictors of early CRC. A validation cohort confirmed calibration and discrimination of the model.

Conclusions: One out of every eight IBD patients with CRC developed their malignancy prior to the currently recommended timeframe for the initiation of surveillance colonoscopy. IBD onset at 28 years or older and tobacco use were identified as predictors of early CRC. Early CRC should be considered in discussions of cancer surveillance in this population. Prospective cohort studies are necessary to further analyze the impact of early CRC in IBD.

Citing Articles

The outcome of patients with inflammatory bowel disease-associated colorectal cancer is not worse than that of patients with sporadic colorectal cancer-a matched-pair analysis of survival.

Vitali F, Wein A, Rath T, Eckstein M, Neufert C, Siebler J Int J Colorectal Dis. 2021; 37(2):381-391.

PMID: 34865179 PMC: 8803672. DOI: 10.1007/s00384-021-04072-9.


Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study.

Klepp P, Brackmann S, Cvancarova M, Hoivik M, Hovde O, Henriksen M BMJ Open Gastroenterol. 2020; 7(1):e000361.

PMID: 32337058 PMC: 7170403. DOI: 10.1136/bmjgast-2019-000361.


Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.

Ehrenberg R, Griffith J, Theigs C, McDonald B J Manag Care Spec Pharm. 2020; 26(6):758-765.

PMID: 32191593 PMC: 10391226. DOI: 10.18553/jmcp.2020.19388.

References
1.
Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M . Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126(2):451-9. DOI: 10.1053/j.gastro.2003.11.010. View

2.
Jussila A, Virta L, Pukkala E, Farkkila M . Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013; 48(12):1405-13. DOI: 10.3109/00365521.2013.846402. View

3.
Lakatos P, Lakatos L . Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008; 14(25):3937-47. PMC: 2725331. DOI: 10.3748/wjg.14.3937. View

4.
Salk J, Bansal A, Lai L, Crispin D, Ussakli C, Horwitz M . Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis. Inflamm Bowel Dis. 2013; 19(12):2593-602. PMC: 3885330. DOI: 10.1097/MIB.0b013e3182a87640. View

5.
Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View